Brain organoids make it possible to observe human neurons under laboratory conditions, study their development and investigate how they form connections. Dr Femke de Vrij discussed her research into neurodevelopmental disorders during a seminar at the Nencki Institute of Experimental Biology of the Polish Academy of Sciences.
Dr de Vrij is a distinguished neuroscientist affiliated with the Department of Psychiatry at Erasmus MC University Medical Center in Rotterdam. Dr Femke de Vrij delivered a lecture presenting her latest findings. She also agreed to share some insights into the advantages of brain organoids, sometimes referred to as “mini-brains”, over conventional neuronal cell cultures in scientific research.
“To create organoids, we use cells obtained from human blood or skin. We take these cells back to an earlier stage of development – a process known as reprogramming – so that they become stem cells,” Dr de Vrij explained. The resulting cells can then be directed to develop into virtually any type of cell required for a particular study.
“In our case, we generate neurons that self-organise into structures resembling an early developing brain. This allows us to investigate how these cells connect with one another and function. However, this does not mean that they can respond to their surroundings or perform tasks that a real brain would be capable of,” the Dutch researcher emphasised.
In her view, the term “brain organoids” is preferable to “mini-brains”, as the structures grown in laboratory dishes do not possess the ability to think. Dr Femke de Vrij’s research focuses on psychiatric disorders.
“We are interested in what happens during brain development in patients with conditions such as schizophrenia. We are also involved in the work of the Encore Expertise Centre, which focuses on neurodevelopmental disorders, particularly in children with intellectual disabilities, often accompanied by epilepsy. We have observed many similarities between these conditions. In some cases, they are genetically linked,” the Dutch researcher explained. This means that inherited genetic mutations may contribute to the development of neurodevelopmental disorders during childhood and may also be associated with the later onset of schizophrenia or paranoia.
“We recently conducted an interesting analysis of a family in which several members had been diagnosed with schizophrenia. We approached the study from two perspectives: first, by examining their genetic profiles, and then by collecting their stem cells and transforming them into brain cells,” Dr de Vrij said.
During DNA analysis, the researchers identified a gene that was likely responsible for the occurrence of schizophrenia in this family. However, they did not observe any abnormalities in the neurons.
“We began to wonder why this was the case. We took a closer look at the function of the gene and discovered that it plays an important role in a specific type of brain cell known as oligodendrocytes. These cells are found in the brain's white matter and are responsible, among other things, for forming the insulating sheaths around nerve fibres.
The problem was that our cell culture did not contain any oligodendrocytes,” the Dutch researcher noted. Once the scientists had also succeeded in generating oligodendrocytes, they identified differences linking the DNA mutation inherited by family members to abnormalities that had also been confirmed through brain imaging studies.
“This is how the idea for developing our own brain organoid model came about, as there are many different types of organoids. Our model was designed to be compact and easy to use in a laboratory plate, allowing us to grow multiple organoids simultaneously,” Dr de Vrij explained. The model can be used, among other things, to test potential treatments and make reliable comparisons between cells, since large numbers of organoids can be generated within a relatively short period of time.
“This allows us to introduce small RNA molecules into cells. This is a form of gene therapy aimed at eliminating toxic proteins. In this way, we can test potential treatments even for extremely rare diseases – including cases in which only a single child in the world carries a particular genetic mutation,” Dr de Vrij emphasised.
Anna Piotrowska
Anna Piotrowska is Head of Communications at the Nencki Institute of Experimental Biology, Polish Academy of Sciences. She is responsible for sharing the Institute’s research and scientific achievements with a wider audience. With years of experience in science communication, she enjoys exploring a wide range of scientific topics and making complex ideas accessible and engaging to the public.
https://nencki.edu.pl/laboratories/communications-and-media-relations-department/